|
KMID : 0624620180510080373
|
|
BMB Reports
2018 Volume.51 No. 8 p.373 ~ p.377
|
|
|
BLT2, a leukotriene B4 receptor 2, as a novel prognostic biomarker of triple-negative breast cancer
|
|
Park Jae-In
Jang Jae-Hyun
Park Geun-Soo
Chung Yun-Ro
You Hye-Jin
Kim Jae-Hong
|
|
|
Abstract
|
|
|
|
Triple-negative breast cancer (TNBC) is considered to be a notorious type of cancer due to its aggressive metastatic potential and poor prognosis. Recent evidence suggests that BLT2, a low-affinity LTB4 receptor is critically associated with the phenotypes of TNBC cells, including invasion, metastasis, and survival. Furthermore, in a group of 545 breast cancer patients with metastasis, we observed that the high-BLT2 subgroup had a lower disease-free-survival rate than the low-BLT2 subgroup. Thus, we theorized that anti-BLT2 strategies could facilitate the development of new therapies used for TNBC. This review focuses on recent discoveries regarding BLT2 and its roles in as a novel prognostic biomarker in TNBC.
|
|
|
KEYWORD
|
|
|
BLT2, Leukotriene B4 receptor-2, TNBC, Triple-negative breast cancer
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|